search button
Open Access

Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)

  • Authors:
    • Ruba A. Hamed
    • Sam Marks
    • Helen Mcelligott
    • Roshni Kalachand
    • Hawa Ibrahim
    • Said Atyani
    • Greg Korpanty
    • Nemer Osman

  • View Affiliations

  • Published online on: December 21, 2021     https://doi.org/10.3892/mco.2021.2472
  • Article Number: 40

  • Copyright: © Hamed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Systemic therapy is the mainstay of treatment for de novo metastatic colorectal cancer (mCRC). Heterogeneity between primary tumours and metastases may lead to discordant responses to systemic therapy at these sites. The aim of the present study was to examine these discrepancies and to evaluate the rates of complications arising from the primary tumour and the strategies employed to manage these complications. Electronic medical records were screened for patients eligible for data analysis between January 1st, 2014 and December 31st, 2019. All patients diagnosed with de novo mCRC with primary tumour in situ at the time of initial systemic therapy were included in data analysis. Responses in primary tumour and metastatic sites (according to the Response Evaluation Criteria In Solid Tumours v1.1), discrepancies in these responses and rates of complications arising from primary tumours were assessed along with patient, pathological or molecular factors that may be associated with these discrepant responses or primary tumour complications. A total of 50 patients were identified (median age, 62 years). Right‑colon, left‑colon and rectal primary tumours comprised 34, 44 and 22% of CRC cases, respectively. All patients received 5‑fluorouracil‑based chemotherapy (either alone or in combination with oxaliplatin or irinotecan). Disease response (DR), stable disease (SD) and progressive disease (PD) were observed as the first response to systemic therapy in 24, 62 and 12% of primary tumours and in 36, 18 and 44% of metastatic sites, respectively. Only 36% of patients demonstrated concordant responses between the primary tumours and metastases, while the remaining 62% demonstrated discordant responses between the primary tumour and distant metastases (22% had DR with SD; 36% had DR or SD with PD; and 4% had PD with SD in the primary tumour and metastases, respectively). Restaging images were not available for 2% of the patients. Approximately 30% of patients developed complications from primary tumours, including bowel obstruction (6.12%), perforation (6%), rectal pain (6%) and rectal bleeding (10%). Approximately 10% of patients underwent palliative stoma creation. Additionally, 12% required palliative radiotherapy to the primary tumour (due to localized complications arising from the tumour). Discordant responses to systemic therapy between primary tumours and metastases occurred in 60% of patients with de novo mCRC (with primary tumour in situ at the time of first systemic therapy). The observations of the present study have potential implications for molecular tissue analysis to help guide systemic therapy. Tissue from metastatic sites may be preferable to confirm biomarker status in mCRC based on this study.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 16 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Hamed RA, Marks S, Mcelligott H, Kalachand R, Ibrahim H, Atyani S, Korpanty G and Osman N: Inoperable <em>de novo</em> metastatic colorectal cancer with primary tumour <em>in situ</em>: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). Mol Clin Oncol 16: 40, 2022
APA
Hamed, R.A., Marks, S., Mcelligott, H., Kalachand, R., Ibrahim, H., Atyani, S. ... Osman, N. (2022). Inoperable <em>de novo</em> metastatic colorectal cancer with primary tumour <em>in situ</em>: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). Molecular and Clinical Oncology, 16, 40. https://doi.org/10.3892/mco.2021.2472
MLA
Hamed, R. A., Marks, S., Mcelligott, H., Kalachand, R., Ibrahim, H., Atyani, S., Korpanty, G., Osman, N."Inoperable <em>de novo</em> metastatic colorectal cancer with primary tumour <em>in situ</em>: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)". Molecular and Clinical Oncology 16.2 (2022): 40.
Chicago
Hamed, R. A., Marks, S., Mcelligott, H., Kalachand, R., Ibrahim, H., Atyani, S., Korpanty, G., Osman, N."Inoperable <em>de novo</em> metastatic colorectal cancer with primary tumour <em>in situ</em>: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)". Molecular and Clinical Oncology 16, no. 2 (2022): 40. https://doi.org/10.3892/mco.2021.2472